Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
December 25, 2022
– FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA – – Junshi Biosciences and Coherus are actively engaged in ongoing discussions with the FDA to support the